salbutamol/ albuterol

Phase 3Small molecule

Novartis

salbutamol/ albuterol is one of 23 small molecule programs targeting Tachypnea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TachypneaActive, not recruiting

AsthmaActive, not recruiting

TachypneaPreclinical

Active, not recruiting

AsthmaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

salbutamol/ albuterol

Novartis

Phase 3

2 2

Cinqair

Teva

Preclinical

13 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

Spiriva

Boehringer Ingelheim

Preclinical

8 5

Formoterol Fumarate

AstraZeneca

Preclinical

8 6

Symbicort

AstraZeneca

Preclinical

6 7

Atrovent

Boehringer Ingelheim

Preclinical

2 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 10

Blood Withdrawn

Emergent BioSolutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ANot yet recruiting

Tachypnea

NCT07350421

Clinical

Trials by Indication[1]

Asthma2 trials

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

Withdrawn· Novartis logo

Novartis·Phase 3·NCT02127697

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

Completed·MMannkind Corporation·Phase 1·NCT00673621·30 enrolled

Tachypnea1 trial

The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN)

Not yet recruiting·TTishreen University·N/A·NCT07350421·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for salbutamol/ albuterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — salbutamol/ albuterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for salbutamol/ albuterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

salbutamol/ albuterol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Asthma2 trials

Tachypnea1 trial

References

Drug Info

Quick Facts

Related News